Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver DrugInvestors Business Daily • 06/23/23
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating ExpensesGlobeNewsWire • 06/23/23
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver DamageGlobeNewsWire • 06/23/23
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASHGlobeNewsWire • 06/22/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/22/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/20/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPTPRNewsWire • 06/15/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/31/23
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/28/23
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)Benzinga • 05/26/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/23/23
Intercept (ICPT) NASH Treatment Fails to Get GIDAC RecommendationZacks Investment Research • 05/22/23
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH DrugInvestors Business Daily • 05/22/23
Intercept Pharmaceuticals stock tumbles toward 11-month low after disappointing FDA committee voteMarket Watch • 05/22/23
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASHGlobeNewsWire • 05/19/23
Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASHGlobeNewsWire • 05/19/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 05/18/23